



FDA Warnings on Codeine and Tramadol in Pediatrics

Ryan Pistoresi, PharmD, MS Assistant Chief Pharmacy Officer Clinical Quality and Care Transformation June 21, 2017





FDA Drug Safety Communication

- On April 20, 2017, the FDA issued a drug safety communication about the risks of using codeine and tramadol products in pediatrics and requiring several changes to the labels of those products.
- An evidence review by the FDA found serious risks associated with these medications and a greater risk for children younger than 12 years of age¹.
- All single-ingredient codeine products and all tramadol products are FDA-approved for use only in adults.





List of Prescription Codeine and Tramadol Pain and Cough Medicines

Medicines Containing Tramadol
Conzip
Ultracet
Ultram
Ultram ER
Generic products containing tramadol

Washington State Health Care Authority

1. Food and Drug Administration. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Department of Health and Human Services. Apr 20 2017.

3



FDA Label Changes

- April 20, 2017 FDA label changes include:
 - Contraindication for <u>codeine</u> to be used to treat pain or cough in children younger than 12 years of age*
 - Contraindication for tramadol to be used to treat pain in children younger than 12 years of age AND to be used to treat pain after surgery to remove the tonsils and/or adenoids in children younger than 18 years of age
 - Warning against use of <u>codeine</u> and <u>tramadol</u> in adolescents between 12 and 18 years of age who are obese or have conditions such as obstructive sleep apnea or severe lung disease
 - Strengthened the Warning against mothers breastfeeding while taking <u>codeine</u> or <u>tramadol</u> due to the risk of serious adverse events in breastfed infants.
- *2013 FDA label changes included:
 - Contraindication for <u>codeine</u> to be used to treat pain after surgery to remove the tonsils and/or adenoids in children younger than 18 years of age





FDA Drug and Safety Communication


- According to the FDA, in 2014:
 - Nearly 1.9 million patients age 18 and younger received a prescription for codeine
 - 1.4 million as analgesic products
 - 483,000 as codeine cough-and-cold products
 - Nearly 167,000 patients age 18 and younger received a prescription for tramadol.








Codeine and Tramadol Utilization







Codeine and Tramadol Utilization



7





Recommendations

- Based on the review of the FDA communication, label changes, and WA FFS utilization, we recommend:
 - codeine and tramadol be placed on prior authorization for patients ages 17 and younger.
 - prior authorization will seek a valid medical reason for why nonpharmacologic, non-opioid pharmaceuticals cannot or should not be used





Motion

• <u>Motion:</u> "I move the Medicaid Fee-for-Service Program implement the limitations for codeine-products and tramadolproducts listed on slide 8 as recommended."

- Motion: Figueroa
- 2nd: Brown
- Vote: Passed







Citations

1. Food and Drug Administration. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Department of Health and Human Services. Apr 20 2017.







Questions?

11

Ryan Pistoresi, PharmD, MS Assistant Chief Pharmacy Officer Clinical Quality and Care Transformation <u>ryan.pistoresi@hca.wa.gov</u> Tel: 360-725-0473

